Spero Therapeutics Inc
SPRO
View Detailed Chart
2.420USD
+0.120+5.22%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
136.27MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+5.22%
5 Days
+10.50%
1 Month
-3.59%
6 Months
+7.08%
Year to Date
+3.86%
1 Year
+180.32%
View Detailed Chart
TradingKey Stock Score of Spero Therapeutics Inc
Currency: USD Updated: 2026-02-06Key Insights
Spero Therapeutics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 103 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 4.00.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Spero Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Spero Therapeutics Inc Highlights
StrengthsRisks
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.
Growing
The company is in a growing phase, with the latest annual income totaling USD 47.98M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 47.98M.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Undervalued
The company’s latest PE is -3.05, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 9.24M shares, decreasing 24.79% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 22.10K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.05.
Analyst Rating
Based on
1
analysts
Hold
Current Rating
4.000
Target Price
+73.91%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Spero Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Spero Therapeutics Inc Info
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.
Ticker SymbolSPRO
CompanySpero Therapeutics Inc
CEORajavelu (Esther)
Websitehttps://sperotherapeutics.com/
Related Instruments
+3.66%
+3.17%
+0.93%
+1.99%
+1.78%
+1.60%
-0.95%
+4.49%
+2.10%
+10.00%
+2.72%
+4.15%
+1.81%
+4.17%
+0.72%
+1.06%
+2.46%
0.00%
+0.53%
+0.56%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
69103.290
-866.840 (-1.24%)
282.580
+22.390 (+8.61%)
2049.660
-2.070 (-0.10%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
